While CDK4/6 inhibitors have been effectively combined with ICI for the treatment of breast cancer, this combination with or without CDK2 inhibition has not yet been demonstrated to be clinically effective for metastatic melanoma. This evidence concerns the gene CDK4 and breast carcinoma.